Vimta Labs (524394) Stock Overview
Provides contract research and testing services in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
524394 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Vimta Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹739.40 |
| 52 Week High | ₹902.85 |
| 52 Week Low | ₹254.43 |
| Beta | -0.24 |
| 1 Month Change | -7.24% |
| 3 Month Change | 57.04% |
| 1 Year Change | 180.16% |
| 3 Year Change | 326.11% |
| 5 Year Change | 1,085.89% |
| Change since IPO | 134,336.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524394 | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 1.1% | 1.8% | 1.5% |
| 1Y | 180.2% | -0.4% | -4.7% |
Return vs Industry: 524394 exceeded the Indian Life Sciences industry which returned -0.4% over the past year.
Return vs Market: 524394 exceeded the Indian Market which returned -4.7% over the past year.
Price Volatility
| 524394 volatility | |
|---|---|
| 524394 Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: 524394's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 524394's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,315 | Harita Vasireddi | vimta.com |
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages.
Vimta Labs Limited Fundamentals Summary
| 524394 fundamental statistics | |
|---|---|
| Market cap | ₹32.93b |
| Earnings (TTM) | ₹717.44m |
| Revenue (TTM) | ₹3.68b |
Is 524394 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524394 income statement (TTM) | |
|---|---|
| Revenue | ₹3.68b |
| Cost of Revenue | ₹900.35m |
| Gross Profit | ₹2.78b |
| Other Expenses | ₹2.06b |
| Earnings | ₹717.44m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 14, 2025
| Earnings per share (EPS) | 16.11 |
| Gross Margin | 75.54% |
| Net Profit Margin | 19.49% |
| Debt/Equity Ratio | 2.2% |
How did 524394 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 20:40 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vimta Labs Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Vijay Madunala | FirstCall Research |